Trial Profile
A Phase 2 Study of a Human Anti-PDGFR-alpha Monoclonal Antibody (IMC-3G3) in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Olaratumab (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in Spain (End Date: 13 Nov 2012), according to European Clinical Trials Database record.
- 14 Feb 2017 Results published in the Annals of Oncology.